- Home
- RPD vs XERS Comparison
RPD vs XERS Comparison
Compare RPD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- XERS
- Stock Information
- Founded
- RPD 2000
- XERS 2005
- Country
- RPD United States
- XERS United States
- Employees
- RPD N/A
- XERS N/A
- Industry
- RPD Computer Software: Prepackaged Software
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- XERS Health Care
- Exchange
- RPD Nasdaq
- XERS Nasdaq
- Market Cap
- RPD 1.3B
- XERS 1.3B
- IPO Year
- RPD 2015
- XERS 2018
- Fundamental
- Price
- RPD $17.82
- XERS $8.33
- Analyst Decision
- RPD Hold
- XERS Strong Buy
- Analyst Count
- RPD 19
- XERS 7
- Target Price
- RPD $27.00
- XERS $8.00
- AVG Volume (30 Days)
- RPD 960.7K
- XERS 2.1M
- Earning Date
- RPD 11-05-2025
- XERS 11-07-2025
- Dividend Yield
- RPD N/A
- XERS N/A
- EPS Growth
- RPD N/A
- XERS N/A
- EPS
- RPD 0.43
- XERS N/A
- Revenue
- RPD $855,361,000.00
- XERS $246,025,000.00
- Revenue This Year
- RPD $2.75
- XERS $43.89
- Revenue Next Year
- RPD $3.21
- XERS $20.40
- P/E Ratio
- RPD $41.35
- XERS N/A
- Revenue Growth
- RPD 4.67
- XERS 35.62
- 52 Week Low
- RPD $17.76
- XERS $2.73
- 52 Week High
- RPD $44.48
- XERS $8.51
- Technical
- Relative Strength Index (RSI)
- RPD 31.65
- XERS 61.63
- Support Level
- RPD $18.56
- XERS $7.88
- Resistance Level
- RPD $19.65
- XERS $8.51
- Average True Range (ATR)
- RPD 0.67
- XERS 0.37
- MACD
- RPD -0.12
- XERS -0.01
- Stochastic Oscillator
- RPD 2.51
- XERS 83.05
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).